|
Completed
|
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 |
|
Enrolling by invitation
|
NCT05132621 -
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
|
|
|
Recruiting
|
NCT05856760 -
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
|
Phase 2 |
|
Recruiting
|
NCT04662723 -
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
|
Phase 4 |
|
Recruiting
|
NCT06291376 -
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
|
Phase 3 |
|
Completed
|
NCT02384317 -
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
|
Phase 2 |
|
Recruiting
|
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 |
|
Active, not recruiting
|
NCT05248646 -
Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
|
Phase 3 |
|
Completed
|
NCT01838239 -
Development of a Metabolic Assessment Tool for Chronic Kidney Disease
|
N/A |
|
Recruiting
|
NCT05852938 -
A Study of BION-1301 in Adults With IgA Nephropathy
|
Phase 3 |
|
Recruiting
|
NCT05834738 -
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
|
Phase 2 |
|
Completed
|
NCT04287985 -
Safety and Efficacy Study of VIS649 for IgA Nephropathy
|
Phase 2 |
|
Recruiting
|
NCT05097989 -
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 |
|
Completed
|
NCT05200871 -
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
|
|
|
Terminated
|
NCT05162066 -
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
|
Phase 2 |
|
Active, not recruiting
|
NCT04573920 -
Atrasentan in Patients With Proteinuric Glomerular Diseases
|
Phase 2 |
|
Withdrawn
|
NCT02605525 -
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
|
Phase 2 |
|
Recruiting
|
NCT04564339 -
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 |
|
Active, not recruiting
|
NCT04573478 -
Atrasentan in Patients With IgA Nephropathy
|
Phase 3 |
|
Active, not recruiting
|
NCT03762850 -
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
|
Phase 3 |